| ID | 1177 |
| Name of the vaccine | rAT and rLukS-PV |
| Microbe | Bacteria |
| Disease name | Methicillin-Resistant Staphylococcus aureus (MRSA) |
| Name of bacteria | Staphylococcus aureus |
| Type of vaccine | Toxoid |
| Nucleic acid content | Circular DNA |
| Age | 18 to 55 years |
| Description of the vaccine | Two S. aureus toxoids - protein rAT and protein rLukS-PV. |
| Name of the manufacturer | Uniformed Services University of the Health Sciences |
| Name of the manufacturing country | United States |
| Year of manufacture | 2011 |
| Clinical Phase status | Clinical - Phase 1, Phase 2 |
| Bacterial strain | Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Single dose of monovalent or bivalent toxoid vaccine. |
| Mechanism of action | NA |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Alum |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01011335 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|